NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA) announced today that its Cogenics division has successfully launched the 454 Genome Sequencer FLX system (the “454 FLX system”) at its facility in Meylan, France, some eight weeks after the signing of the co-marketing agreement with Roche Diagnostics Inc., to offer “next generation” sequencing services. The system enhances Cogenics’ portfolio of services by providing whole genome sequencing, Expressed Sequence Tag sequencing, identification of small RNAs, transcriptome analysis, and metagenomics on the new platform.
